Image source: Adobe Stock/Kateryna_Kon

News • Potential of immunotherapy explored

Surgery first for colon cancer? Not so fast, says new study

New research in the Journal of the National Comprehensive Cancer Network (JNCCN) finds that immunotherapy from immune checkpoint (PD-1) inhibitors prior to surgery was strikingly effective for patients with localized mismatch repair-deficient or microsatellite instability-high (dMMR/MSI-H) colorectal cancer (CRC).

Nearly all of the patients studied benefitted from neoadjuvant PD-1 inhibitors, with 1-of-4 experiencing complete response on clinical assessment. In addition to the short-term effectiveness, the findings showed substantial longer survival benefits from neodjuvant PD-1 inhibitors, including a low recurrence rate when compared with historic rates. 

Complimentary access to the study in JNCCN is available until April 10, 2023. 

The researchers—who are based in Southern China—anticipated PD-1 inhibitors could be at least as effective for locally-advanced but operable cancer as they have historically been in the treatment of metastatic dMMR/MSI-H CRC, but were surprised to find it so much more effective for this patient population. The study included a retrospective review of 73 patients between ages 18 and 75 with confirmed dMMR/MSI-H CRC who received any type of PD-1 inhibitor prior to surgery between October 1, 2017 and December 31, 2021. Of those 73, 48 were diagnosed with colon cancer, 18 with rectal cancer, and 7 with multiple types of CRC. 84.9% overall experienced an objective response, with 23.3% showing complete response and 61.6% partial response. The 2-year rates for tumor-specific overall survival and disease-free survival were 100% for patients who underwent surgery after PD-1 blockade.

portrait of Pei-Rong Ding
Pei-Rong Ding, MD

Image source: NCCN

“We need to keep in mind that our final goal is to cure patients long term, not just remove the tumor at the moment,” said senior author Pei-Rong Ding, MD, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine. “I think care providers, especially surgeons, should refrain from scheduling immediate surgery for patients with locally advanced, or even early-stage dMMR/MSI-H colorectal cancer. With such a powerful option at hand, we have the duty to offer a safer surgery with better outcomes or a non-surgical-yet-equally-effective approach for this group of patients, especially for those who might suffer from function damage or organ sacrifice after surgery.” 

The study had an average follow-up time of 17.2 months, with 16 patients tracked for more than two years. The researchers call for more studies with an even longer follow-up to confirm these results, especially after treatment ends. There is also more to learn about the long-term safety of this approach and possible implications for limiting or avoiding surgery entirely. 

"The treatment of mismatch repair deficient locally-advanced colorectal cancer is a highly active area of research,” commented Dustin A. Deming, MD, University of Wisconsin Carbone Cancer Center, Member of the NCCN Guidelines Panel for Colon/Rectal/Anal Cancers, who was not involved in this study. “This retrospective analysis highlights the potential for significant treatment responses with limited toxicities for these patients treated with immune checkpoint inhibitors. It will be exciting to see how these results, and other completed and on-going studies, will be utilized to incorporate anti-PD1 treatments into the standard-of-care for locally-advanced colorectal cancers." 


Source: National Comprehensive Cancer Network

13.01.2023

Read all latest stories

Related articles

Photo

News • Prevention measure scrutinised

Colorectal cancer: colonoscopy screening not as effective as previously believed

A randomized study shows colonoscopy screening reduces the risk of colorectal cancer by 18 percent. The reduction is much smaller than experts previously assumed.

Photo

News • Better outcomes, fewer costs

Experts propose less invasive bowel cancer treatment approach

New research suggests that providing a break in treatment to patients with advanced bowel cancer could not only benefit a patient’s quality of life but could also help reduce costs.

Photo

News • Automated adenoma analysis

AI finds more precancerous polyps than traditional colonoscopy

Colonoscopies performed with AI support may yield an increase in the overall rate of detection of adenoma, or cancerous and precancerous polyps, by 27% in average-risk patients, according to new data.

Related products

Alphenix 4D CT

Multi-Modality Suites

Canon · Alphenix 4D CT

Canon Medical Systems Europe B.V.
Aquilion Exceed LB

Oncology CT

Canon · Aquilion Exceed LB

Canon Medical Systems Europe B.V.
Aquilion LB

Oncology CT

Canon · Aquilion LB

Canon Medical Systems Europe B.V.
Arcovis 3000 S / R

Surgical II-C-Arms

Villa Sistemi Medicali · Arcovis 3000 S / R

VILLA SISTEMI MEDICALI s.p.a.
Cios Alpha

Surgical Flat Panel C-Arms

Siemens Healthcare · Cios Alpha

Siemens Healthcare GmbH
Cios Flow

Surgical Flat Panel C-Arms

Siemens Healthcare · Cios Flow

Siemens Healthcare GmbH
Subscribe to Newsletter